Author:
Wahyuni Siska Dwiyantie,Suryanti Sri,Agustina Hasrayati,Hernowo Bethy Suryawathy
Abstract
Background: Infiltrative urothelial carcinoma of bladder is an aggressive variant of bladder carcinoma. Most of the patients in their first encounter with doctors are diagnosed with advanced stages and many has metastasized. Metastasis is a process of malignant tumor cells migrating from its primary tumor location to other organs or sites inside the body via blood circulation or lymphatic system. Metastasis process is responsible for 90% cancer deaths compared to the primary tumor itself, infiltrative urothelial carcinoma of bladder. To reduce mortality, knowledge of the clinicopathological characteristics associated with metastasis is needed.
Method: Research material used was clinical data and paraffin block from patients with metastatic and non-metastatic infiltrative urothelial carcinoma of bladder. Clinical data taken from Central Medical Record Installation and Urology Medical Record Installation Padjadjaran University/ Dr. Hasan Sadikin Hospital Bandung, Indonesia. Paraffin blocks were obtained from operations at Hasan Sadikin Hospital Bandung, Indonesia.Total data sample obtained were 40 samples, 20 samples are metastatic and another 20 are non-metastatic samples. Clinicopathological parameters included in the analysis were age, sex and pathalogical T stage.
Result: Pathalogical T stage have associations with metastatic status with significant result with p value=0.035 (p<0.005).
Conclusion: Pathalogical T stage was associated with the metastatic status of Infiltrative urothelial carcinoma of bladder and may play important roles during the metastatic process. Thus, it can be used as a predictor factor for the infiltrative urothelial carcinoma of bladder.
Keywords: infiltrative urothelial carcinoma of bladder, metastastic, pathalogical T stage
Publisher
Society of Pharmaceutical Tecnocrats
Reference16 articles.
1. 1. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Medical sciences (Basel, Switzerland). 2020 Mar 13; 8(1).
2. 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov; 68(6):394-424.
3. 3. Fred T. Bosman MP ESJM, Sunil R.Lakhani MF, Hiroko Ohgaki. P.Tumours of the urinary tract. In: Holger Moch PAH, Thomas M.U I bright, Victor E.Reuter (Eds), editor. WHO Classification of Tumours of the Urinary System and Male Genital Organs.4 ed.Lyon, France: International Agency for Research on Cancer (IARC) Press: International Agency for Research on Cancer (IARC) Press; 2016.hlm.77-106. 2016; 77-106.
4. 4. Cheng L, Lopez-Beltran A, Bostwick DG. Bladder Pathology: John Wiley & Sons; 2012.
5. 5. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2017 Oct; 24(10):730-4.